Slingshot Insights | Gern Overview

GERN Overview

Upcoming Projects (GERN)

Don’t see a project related to the company you care about? Create your own!

Executed Projects (GERN)

Discussing new data available from ASCO 2023 on MDS with a focus on Bristol Myers' Reblozyl (luspatercept) COMMANDS trial and Geron's imetelstat IMerge Phase 2/3 study in patients with LR-MDS.
Tickers: BMY, GERN
Executed On: Jun 20, 2023 at 05:00 PM EDT
A Second Opinion: Discussing new data available from ASCO 2023 on MDS with a focus on Bristol Myers' Reblozyl (luspatercept) COMMANDS trial and Geron's imetelstat IMerge Phase 2/3 study in patients with LR-MDS.
Tickers: BMY, GERN
Executed On: Jun 16, 2023 at 09:00 AM EDT
A second look: Discussing the potential of imetelstat, a first-in-class telomerase inhibitor, for treatment in patients with multiple myeloma who are relapsed, refractory or ineligible for erythropoiesis stimulating agents.
Ticker: GERN
Executed On: Mar 13, 2023 at 12:00 PM EDT
Discussing the potential of imetelstat, a first-in-class telomerase inhibitor, for treatment in patients with multiple myeloma who are relapsed, refractory or ineligible for erythropoiesis stimulating agents.
Ticker: GERN
Executed On: Feb 15, 2023 at 04:00 PM EST

Upcoming & Overdue Catalysts (GERN)

Don’t see a catalyst related to the company you care about? Create your own!

Strategic Initiatives (GERN)

Don’t see a strategic initiative related to the company you care about? Create your own!